Rohto Wants to Wrap Up PII of COVID-19 Cell Therapy in 2022: President

Rohto Pharmaceutical hopes to complete its ongoing Japan PII study of the allogeneic mesenchymal stem cell (MSC) therapy ADR-001 for COVID-19 by the end of next year, President Masashi Sugimoto said on November 11. “Initially, we were able to enroll...read more